Report: Annual VC investment in genomics companies rises 142% since 2016

Genomics companies in the U.S. received $2.52 billion in venture capital funding in 2017, up 142 percent from $1.04 billion in 2016, according to a joint report by PwC and CB Insights.

The majority of the $2.52 billion in funding, roughly $1.7 billion, went toward companies focused on disease diagnosis. The second most-funded genomics sector was biotechnology at $550 million.

Here are the five genomics companies that received the most VC funding during the fourth quarter of 2017.

1. Menlo Park, Calif.-based Grail: $238 million

2. South San Francisco, Calif.-based Counsyl: $80 million

3. Baltimore-based Personal Genome Diagnostics: $65 million

4. Burlingame, Calif.-based Color Genomics: $37 million

5. Atlanta-based Prelude Fertility: $10 million

More articles on data analytics & precision medicine:
Report: 5 states with highest, lowest demand for data science jobs
Indiana U to launch statewide addiction database project
Survey: More than 80% of payers integrate social determinants of health data into programs

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers